[{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enisamium Iodide","moa":"Influenza virus RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enisamium Iodide","moa":"Influenza virus RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farmak JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Farmak JSC \/ Undisclosed"},{"orgOrder":0,"company":"Farmak JSC","sponsor":"Sunshine Guojian Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Farmak JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Farmak JSC \/ Sunshine Guojian Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Farmak JSC \/ Sunshine Guojian Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Farmak JSC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Meloxicam is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Meloxicam

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Progesterone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Progesterone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Progesterone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Progesterone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Clopidogrel Bisulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Clopidogrel

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Olanzapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 17, 2021

                          Lead Product(s) : Olanzapine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 17, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Cell Bio
                          Not Confirmed
                          Cell Bio
                          Not Confirmed

                          Details : Enisamium Iodide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 24, 2020

                          Lead Product(s) : Enisamium Iodide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank